Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Threshold Analysis and Biodistribution of Fluorescently Labeled Bevacizumab in Human Breast Cancer.
Koch M, de Jong JS, Glatz J, Symvoulidis P, Lamberts LE, Adams AL, Kranendonk ME, Terwisscha van Scheltinga AG, Aichler M, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WP, Van der Wall E, Garcia-Allende PB, van Diest PJ, de Vries EG, Walch A, van Dam GM, Ntziachristos V. Koch M, et al. Among authors: lamberts le. Cancer Res. 2017 Feb 1;77(3):623-631. doi: 10.1158/0008-5472.CAN-16-1773. Epub 2016 Nov 22. Cancer Res. 2017. PMID: 27879266
Tumor-Specific Uptake of Fluorescent Bevacizumab-IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study.
Lamberts LE, Koch M, de Jong JS, Adams ALL, Glatz J, Kranendonk MEG, Terwisscha van Scheltinga AGT, Jansen L, de Vries J, Lub-de Hooge MN, Schröder CP, Jorritsma-Smit A, Linssen MD, de Boer E, van der Vegt B, Nagengast WB, Elias SG, Oliveira S, Witkamp AJ, Mali WPTM, Van der Wall E, van Diest PJ, de Vries EGE, Ntziachristos V, van Dam GM. Lamberts LE, et al. Clin Cancer Res. 2017 Jun 1;23(11):2730-2741. doi: 10.1158/1078-0432.CCR-16-0437. Epub 2016 Nov 9. Clin Cancer Res. 2017. PMID: 28119364 Clinical Trial.
Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ, Terwisscha van Scheltinga AG, Kosterink JG, Pot L, Vedelaar SR, Lamberts LE, Williams SP, Lub-de Hooge MN, de Vries EG. ter Weele EJ, et al. Among authors: lamberts le. Oncotarget. 2015 Dec 8;6(39):42081-90. doi: 10.18632/oncotarget.5877. Oncotarget. 2015. PMID: 26536664 Free PMC article.
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
Lamberts LE, Menke-van der Houven van Oordt CW, ter Weele EJ, Bensch F, Smeenk MM, Voortman J, Hoekstra OS, Williams SP, Fine BM, Maslyar D, de Jong JR, Gietema JA, Schröder CP, Bongaerts AH, Lub-de Hooge MN, Verheul HM, Sanabria Bohorquez SM, Glaudemans AW, de Vries EG. Lamberts LE, et al. Clin Cancer Res. 2016 Apr 1;22(7):1642-52. doi: 10.1158/1078-0432.CCR-15-1272. Epub 2015 Nov 20. Clin Cancer Res. 2016. PMID: 26589435
89Zr-Lumretuzumab PET Imaging before and during HER3 Antibody Lumretuzumab Treatment in Patients with Solid Tumors.
Bensch F, Lamberts LE, Smeenk MM, Jorritsma-Smit A, Lub-de Hooge MN, Terwisscha van Scheltinga AGT, de Jong JR, Gietema JA, Schröder CP, Thomas M, Jacob W, Abiraj K, Adessi C, Meneses-Lorente G, James I, Weisser M, Brouwers AH, de Vries EGE. Bensch F, et al. Among authors: lamberts le. Clin Cancer Res. 2017 Oct 15;23(20):6128-6137. doi: 10.1158/1078-0432.CCR-17-0311. Epub 2017 Jul 21. Clin Cancer Res. 2017. PMID: 28733442 Free PMC article. Clinical Trial.
Molecular imaging for monitoring treatment response in breast cancer patients.
Bensch F, van Kruchten M, Lamberts LE, Schröder CP, Hospers GA, Brouwers AH, van Vugt MA, de Vries EG. Bensch F, et al. Among authors: lamberts le. Eur J Pharmacol. 2013 Oct 5;717(1-3):2-11. doi: 10.1016/j.ejphar.2013.01.079. Epub 2013 Mar 30. Eur J Pharmacol. 2013. PMID: 23545359 Review.
Antibody positron emission tomography imaging in anticancer drug development.
Lamberts LE, Williams SP, Terwisscha van Scheltinga AG, Lub-de Hooge MN, Schröder CP, Gietema JA, Brouwers AH, de Vries EG. Lamberts LE, et al. J Clin Oncol. 2015 May 1;33(13):1491-504. doi: 10.1200/JCO.2014.57.8278. Epub 2015 Mar 16. J Clin Oncol. 2015. PMID: 25779566 Review.
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial.
Gebhart G, Lamberts LE, Wimana Z, Garcia C, Emonts P, Ameye L, Stroobants S, Huizing M, Aftimos P, Tol J, Oyen WJ, Vugts DJ, Hoekstra OS, Schröder CP, Menke-van der Houven van Oordt CW, Guiot T, Brouwers AH, Awada A, de Vries EG, Flamen P. Gebhart G, et al. Among authors: lamberts le. Ann Oncol. 2016 Apr;27(4):619-24. doi: 10.1093/annonc/mdv577. Epub 2015 Nov 23. Ann Oncol. 2016. PMID: 26598545 Free article. Clinical Trial.
15 results